Pharma Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ChemGenex Pharmaceuticals
ChemGenex discovery highlighted at international diabetes conference
July 4th, 2006
ChemGenex Pharmaceuticals (CXS; CXSP) announced that John Blangero, PhD, senior director of statistical genomics, presented new data on the PSARL gene at the Annual Meeting of the American Diabetes Association in Washington. Blangero's presentation formed part of an expert symposium on mitochondrial dysfunction. It has become increasingly clear that mitochondrial function is integral in the development of type 2 diabetes and Blangero presented recent data and expanded on previous reports that a variant in the human PSARL gene is responsible for a significant proportion of the increase in diabetes risk found with aging. "PSARL is...
Source: Pharma Law Weekly (2006-07-04)
|
